http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Princeton, NJ and San Diego, CA, November 12, 2009--Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening... http://pharmalicensing.com/redirs/news_rss//public/news/view/499708/0/7/tobira-therapeutics-inc-announce-presentation-of-tbr-652-data-at-european-aids-conference http://pharmalicensing.com/redirs/news_rss//public/news/view/499708/0/7/tobira-therapeutics-inc-announce-presentation-of-tbr-652-data-at-european-aids-conference Montr http://pharmalicensing.com/redirs/news_rss//public/news/view/499756/0/7/theratechnologies-presents-combined-phase-3-clinical-results-at-european-aids-conference http://pharmalicensing.com/redirs/news_rss//public/news/view/499756/0/7/theratechnologies-presents-combined-phase-3-clinical-results-at-european-aids-conference MENLO PARK, Calif., November 11, 2009 - Geron Corporation (Nasdaq: GERN) today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem... http://pharmalicensing.com/redirs/news_rss//public/news/view/499783/0/7/geron-collaborators-publish-data-on-hesc-derived-glial-progenitor-cell-therapy-in-cervical-spinal-cord-injury http://pharmalicensing.com/redirs/news_rss//public/news/view/499783/0/7/geron-collaborators-publish-data-on-hesc-derived-glial-progenitor-cell-therapy-in-cervical-spinal-cord-injury November 11, 2009--A recent paper, by researchers at Genentech, describes the preclinical evaluation of the pharmacokinetic properties of GDC-0449, a potent selective Hedgehog signalling pathway... http://pharmalicensing.com/redirs/news_rss//public/news/view/499713/0/7/simcyp-simulator-aids-in-preclinical-adme-assessment-of-genentech-compound http://pharmalicensing.com/redirs/news_rss//public/news/view/499713/0/7/simcyp-simulator-aids-in-preclinical-adme-assessment-of-genentech-compound November 04, 2009--The development of an effective prophylactic vaccine against herpes simplex virus (HSV) is a key product opportunity for which the AlphaVax vector platform is ideally suited. [HSV... http://pharmalicensing.com/redirs/news_rss//public/news/view/498866/0/7/alphavax-progresses-a-prophylactic-hsv-vaccine http://pharmalicensing.com/redirs/news_rss//public/news/view/498866/0/7/alphavax-progresses-a-prophylactic-hsv-vaccine Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive... http://pharmalicensing.com/redirs/news_rss//public/news/view/498588/0/7/viiv-healthcare-launches-a-new-specialist-hiv-company-dedicated-to-delivering-advances-in-hiv-treatment-and-care http://pharmalicensing.com/redirs/news_rss//public/news/view/498588/0/7/viiv-healthcare-launches-a-new-specialist-hiv-company-dedicated-to-delivering-advances-in-hiv-treatment-and-care RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho)... http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/7/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test http://pharmalicensing.com/redirs/news_rss//public/news/view/499817/0/7/ortho-clinical-diagnostics-launches-fetalscreen-tm-ii-fetal-maternal-hemorrhage-screening-test October 22, 2009--Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Cancer Vac Pty Ltd, has received a Decision to Grant from the... http://pharmalicensing.com/redirs/news_rss//public/news/view/497059/0/7/prima-biomed-secures-japanese-patent-for-cancer-vac http://pharmalicensing.com/redirs/news_rss//public/news/view/497059/0/7/prima-biomed-secures-japanese-patent-for-cancer-vac Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its... http://pharmalicensing.com/redirs/news_rss//public/news/view/496658/0/7/crucell-hiv-vaccine-promising-preliminary-results-phase-i-study-presented-by-dr-dan-barouch-at-aids-vaccine-2009-in-paris http://pharmalicensing.com/redirs/news_rss//public/news/view/496658/0/7/crucell-hiv-vaccine-promising-preliminary-results-phase-i-study-presented-by-dr-dan-barouch-at-aids-vaccine-2009-in-paris Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two... http://pharmalicensing.com/redirs/news_rss//public/news/view/496674/0/7/two-new-appointments-to-bioalliance-pharmas-supervisory-board-in-phase-with-the-companys-development http://pharmalicensing.com/redirs/news_rss//public/news/view/496674/0/7/two-new-appointments-to-bioalliance-pharmas-supervisory-board-in-phase-with-the-companys-development